Posted in | News | Gold

Freegold Ventures Reports Phase I Assay Results from Dolphin Zone

Freegold Ventures has reported the assay results of the last three holes from the phase I drilling conducted at the Dolphin Zone, Alaska.

The company has drilled 6,328 m, totaling 28 holes, during the phase I drilling campaign. The plan of this drill program was to extend the prominent resource and improve the resource category. The company is anticipating the completion of an updated NI-43-101 resource calculation of the Dolphin zone during 2011. The holes drilled during phase I program were situated in and were contiguous to the Dolphin Zone’s major intrusive and were planned in such a way as to extend the resource to depth, the east and the south.

The company has intersected 0.68 g/t gold over 452 m in the hole GSDC 11-32, 1.03 g/t gold over 149.2 m in the hole GSDC 11-47, 2.3 g/t gold over 74.1 m and 1.00 g/t gold over 207.4 m in the hole GSDC 11-38, 0.65 g/t gold over 187 m in the hole GSDC 11-41 and 0.68 g/t gold over 56.1 m in the hole GSDC 11-51.

ALS Chemex has tested the core samples by means of fire assay analysis for gold and multi element ICP-MS and ICP-AES analysis utilizing four-axis digestion technique.

Freegold commenced a phase II drill campaign during mid August and may continue drilling till March, 2012. It is also drilling at the Cleary Hill mine prospect, wherein 15 holes have been drilled. The company is expecting to prepare an initial NI 43-101 resource in that region.

Besides drilling at the Golden summit, the company drilled three holes, totaling 2,984 ft, at the Rob Gold project and is waiting for the assay results.

Joel Scanlon

Written by

Joel Scanlon

Joel relocated to Australia in 1995 from the United Kingdom and spent five years working in the mining industry as an exploration geotechnician. His role involved utilizing GIS mapping and CAD software. Upon transitioning to the North Coast of NSW, Australia, Joel embarked on a career as a graphic designer at a well-known consultancy firm. Subsequently, he established a successful web services business catering to companies across the eastern seaboard of Australia. It was during this time that he conceived and launched News-Medical.Net. Joel has been an integral part of AZoNetwork since its inception in 2000. Joel possesses a keen interest in exploring the boundaries of technology, comprehending its potential impact on society, and actively engaging with AI-driven solutions and advancements.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Freegold Ventures Limited. (2019, February 18). Freegold Ventures Reports Phase I Assay Results from Dolphin Zone. AZoMining. Retrieved on November 22, 2024 from https://www.azomining.com/News.aspx?newsID=5355.

  • MLA

    Freegold Ventures Limited. "Freegold Ventures Reports Phase I Assay Results from Dolphin Zone". AZoMining. 22 November 2024. <https://www.azomining.com/News.aspx?newsID=5355>.

  • Chicago

    Freegold Ventures Limited. "Freegold Ventures Reports Phase I Assay Results from Dolphin Zone". AZoMining. https://www.azomining.com/News.aspx?newsID=5355. (accessed November 22, 2024).

  • Harvard

    Freegold Ventures Limited. 2019. Freegold Ventures Reports Phase I Assay Results from Dolphin Zone. AZoMining, viewed 22 November 2024, https://www.azomining.com/News.aspx?newsID=5355.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.